Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kineta, Inc. (KANT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: KANT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.05% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.07M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 12760 | Beta -3.66 | 52 Weeks Range 0.26 - 1.15 | Updated Date 03/29/2025 |
52 Weeks Range 0.26 - 1.15 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -148.19% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5881420 | Price to Sales(TTM) - |
Enterprise Value 5881420 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 1.29 | Enterprise Value to EBITDA -4.53 | Shares Outstanding 12265500 | Shares Floating 7987147 |
Shares Outstanding 12265500 | Shares Floating 7987147 | ||
Percent Insiders 34.84 | Percent Institutions 5.25 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kineta, Inc.
Company Overview
History and Background
Kineta, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies in oncology. Founded in 2007, Kineta's initial focus was on antiviral research, later shifting to immuno-oncology. Key milestones include preclinical and clinical development of various drug candidates targeting the immune system to fight cancer.
Core Business Areas
- Oncology: Kineta focuses on developing novel immunotherapies to treat cancer by modulating the immune system to recognize and attack cancer cells. Their pipeline includes programs targeting both innate and adaptive immunity.
Leadership and Structure
Kineta is led by Shawn Iadonato, Ph.D., CEO. The company's structure involves a scientific advisory board and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- KVA078 (Claudin-18.2 targeting immunotherapy): A fully human monoclonal antibody targeting Claudin-18.2, a protein overexpressed in certain cancers like gastric and pancreatic cancer. Currently in clinical trials for solid tumors. Market share data is not publicly available. Competitors include companies developing Claudin-18.2 targeted therapies, such as Astellas Pharma (IMAB362) and BioNTech (BNT211). Revenue is currently $0 since it is in clinical development.
- KIR (KIR targeting antibodies): Kineta is developing KIR targeting antibodies designed to reverse immune suppression and activate NK cells and T cells to destroy cancer. Currently in preclinical development. Market share data is not publicly available. Competitors include companies focused on NK cell therapies and immune checkpoint inhibitors. Revenue is currently $0 since it is in preclinical development.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by the success of checkpoint inhibitors and the increasing understanding of the tumor microenvironment. There's a high demand for novel therapies that can overcome resistance to existing treatments.
Positioning
Kineta is positioned as a company focused on developing novel immunotherapies targeting key mechanisms in the tumor microenvironment. Its competitive advantage lies in its proprietary drug discovery platform and focus on unmet medical needs in oncology.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars. Kineta is positioned to capture a portion of this TAM with its pipeline of novel therapies targeting specific cancer indications. Total Addressable Market is expected to surpass $150B by 2027.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy pipeline
- Proprietary drug discovery platform
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
- Early-stage development pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new cancer indications
- Advancements in immunotherapy technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
Competitive Landscape
Kineta competes in a crowded immuno-oncology landscape dominated by large pharmaceutical companies. Its innovative approach and targeted therapies could offer a competitive edge if clinical trials are successful.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Kineta's historical growth is characterized by advancement in its pipeline.
Future Projections: Future growth depends on the success of its clinical trials and potential partnerships.
Recent Initiatives: Focus on advancing clinical trials for KVA078 and preclinical development of KIR targeting antibodies.
Summary
Kineta, Inc. is a clinical-stage biotech company with a focus on developing novel immunotherapies for cancer. The company's strength lies in its innovative pipeline and targeted therapeutic approaches. However, it faces challenges related to limited financial resources and competition from larger companies. Successful clinical trial outcomes and strategic partnerships are crucial for Kineta's future growth.
Similar Companies
- AGEN
- NK
- CRIS
- XOMA
Sources and Disclaimers
Data Sources:
- Kineta, Inc. SEC Filings (10-K, 10-Q)
- Company website
- Analyst reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered as investment advice. Market share data is estimated based on available information. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kineta, Inc.
Exchange NASDAQ | Headquaters Mercer Island, WA, United States | ||
IPO Launch date 2016-02-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://kinetabio.com |
Full time employees 4 | Website https://kinetabio.com | ||
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.